Laurus Labs has signed definitive agreements to acquire additional stake of 7.24% in Immunoadoptive Cell Therapy (lmmunoACT), an advanced cell and gene therapy company for a cash consideration of Rs 80 crore.
Post the completion of the deal, Laurus Labs’ stake in ImmunoACT will increase to 33.86% (on fully diluted basis). This fresh infusion of capital will enable ImmunoACT to fast track the additional supply of the lead candidate HCAR-19 along with the further expansion of the multi-location GMP facilities for manufacturing Chimeric Antigen Receptor T cells (CAR-T cells) treatment to support the growing need for scalable manufacturing.
Laurus Labs is a leading research and development driven pharmaceutical company in India. The company has grown consistently to become one of the leading manufacturers of APIs for anti-retroviral (ARV) and Hepatitis C. It also manufactures APIs in oncology and other therapeutic areas.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1861.70 |
Dr. Reddys Lab | 1389.35 |
Cipla | 1506.15 |
Lupin | 2228.00 |
Zydus Lifesciences | 972.70 |
View more.. |